Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)

References

• Justice RW, Zilian O, Woods DF, et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9:534–536.
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan K. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73–79.
   PubMed Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, and Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29:783–803.
   PubMed Web of Science ®Google Scholar
• Johnson R, Halder G. The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63–79.
   PubMed Web of Science ®Google Scholar
• Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211–226.
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, and Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19:480–494.
   PubMed Web of Science ®Google Scholar
• Sahu MR, Mondal AC. The emerging role of hippo signaling in neurodegeneration. J Neurosci Res. 2020;98:796–814.
   PubMed Web of Science ®Google Scholar
• Jin J, Zhao X, Fu H, et al. The effects of YAP and its related mechanisms in central nervous system diseases. Front Neurosci. 2020;14:595.
   PubMedGoogle Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287–1312.
   PubMed Web of Science ®Google Scholar
• Koo JH, Guan KL. Interplay between YAP/TAZ and metabolism. Cell Metab. 2018;28:196–206.
   PubMed Web of Science ®Google Scholar
• Yamaguchi N. Multiple roles of vestigial-like family members in tumor development. Front Oncol. 2020;10:1266.
   PubMedGoogle Scholar
• Li Z, Zhao B, Wang P, et al. Structural Insights into the YAP and TEAD complex. Genes Dev. 2010;24:235–240.
   PubMed Web of Science ®Google Scholar
• Hau JC, Erdmann D, Mesrouze Y, et al. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences. ChemBioChem. 2013;14:1218–1225.
   PubMedGoogle Scholar
• Bokhovchuk F, Mesrouze Y, Izaac A, et al. Molecular and structural characterization of a TEAD mutation at the origin of sveinsson’s chorioretinal atrophy. FEBS J. 2019;286:2381–2398.
   PubMedGoogle Scholar
• Gibault F, Sturbaut M, Bailly F, et al. Targeting Transcriptional Enhanced Associate Domains (TEADs). J Med Chem. 2018;61:5057–5072.
   PubMedGoogle Scholar
• Chan P, Han X, and Zheng B, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the hippo pathway. Nat Chem Biol. 2016;12:282–289.
   PubMed Web of Science ®Google Scholar
• Noland CL, Gierke S, Schnier PD, et al. Palmitoylation of TEAD transcription factors is required for their stability and function in hippo pathway signaling. Structure. 2016;24:179–186.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
   PubMed Web of Science ®Google Scholar
• Lam-Himlin DM, Daniels JA, Gayyed MF, et al. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int. J. Gastrointest. Cancer. 2006;37. 103–109.
   PubMedGoogle Scholar
• Menzel M, Meckbach D, Weide B, et al. In melanoma, hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. Pigment Cell Melanoma Res. 2014;27:671–673.
   PubMedGoogle Scholar
• Fujii M, Toyoda T, Nakanishi H, et al. TGF- beta synergizes with defects in the hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209:479–494.
   PubMedGoogle Scholar
• Wang Q, Xu Z, An Q, et al. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep. 2015;11:982–988.
   PubMedGoogle Scholar
• Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554:62–68.
   PubMed Web of Science ®Google Scholar
• Lee H, Hwang SJ, Kim RH, et al. Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta. 2016;1859:599–611.
   PubMed Web of Science ®Google Scholar
• Sekido Y. Targeting the hippo pathway is a new potential therapeutic modality for malignant mesothelioma. Cancers (Basel). 2018;10:90.
   Google Scholar
• Li Q, Sun Y, Jarugumilli GK, et al. Lats1/2 sustain intestinal stem cells and Wnt activation through TEAD-dependent and independent transcription. Cell Stem Cell. 2020;26:675–692.e8.
   PubMedGoogle Scholar
• The General Hospital Corporation. TEAD transcription factor autopalmitoylation inhibitors. WO2017053706; 2017
   Google Scholar
• Crawford JJ, Bronner SM, Zbieg JR. Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review. Expert Opin Ther Pat. 2018;28:867–873.
   PubMed Web of Science ®Google Scholar
• The General Hospital Corporation. Novel small molecule inhibitors of TEAD transcription factors. WO2020190774; 2020
   Google Scholar
• Dana Farber Cancer Institute. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses there of. WO2020081572; 2020
   Google Scholar
• Kurppa KJ, Liu Y, To C, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37:104–122.e12.
   PubMed Web of Science ®Google Scholar
• Dana Farber Cancer Institute. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof. WO2021133896; 2020.
   Google Scholar
• Dana Farber Cancer Institute. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses there of. WO2021247634, 2021
   Google Scholar
• Bum-Erdene K, Zhou D, Gonzalez-Gutierrez G, et al. Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD⋅Yap protein-protein interaction. Cell Chem Biol. 2019;26:378–389.e13.
   PubMedGoogle Scholar
• Indianapolis University. Compounds and methods to attenuate tumor progression and metastasis. WO2020087063; 2020
   Google Scholar
• Inventiva. New compounds inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma. WO2017064277; 2017
   Google Scholar
• Inventiva. New compounds inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma. WO2018185266; 2018
   Google Scholar
• Inventiva. Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer. WO2020070181; 2020
   Google Scholar
• Zhou W, Li Y, Song J, et al. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP–TEAD protein–protein interface 3. Anal Biochem. 2019;586:113413.
   PubMedGoogle Scholar
• University of California. Inhibitors of hippo-YAP signaling pathway. WO2013188138; 2013
   Google Scholar
• Song S, Xie M, Scott AW, et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther. 2018;17:443‑54.
   Google Scholar
• Vivace Therapeutics Inc. Tricyclic compounds. WO2017058716; 2017
   Google Scholar
• Vivace Therapeutics Inc. Non-fused tricyclic compounds. WO2018204532; 2018
   Google Scholar
• Vivace Therapeutics Inc. Benzosulfonyl compounds. WO2019040380; 2019
   Google Scholar
• Vivace Therapeutics Inc. Benzocarbonyl compounds. WO2019113236; 2019
   Google Scholar
• Vivace Therapeutics Inc. Oxadiazole compounds. WO2019222431; 2019
   Google Scholar
• Vivace Therapeutics Inc. Bicyclic compounds. WO2020097389; 2020
   Google Scholar
• Vivace Therapeutics Inc. Bicyclic compounds. WO2020214734; 2020
   Google Scholar
• Vivace Therapeutics Inc. Heteroaryl compounds. WO2021102204; 2021
   Google Scholar
• Tang TT, Konradi AW, and Feng Y, et al. Small molecule inhibitors of TEAD Auto-Palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol Cancer Ther. 2021;20:986–998.
   PubMedGoogle Scholar
• Genentech. Therapeutic compounds. WO2019232216; 2019
   Google Scholar
• Genentech. Carboxamide and sulfonamide derivatives useful as TEAD modulators. WO2020051099; 2020
   Google Scholar
• Holden JK, Crawford JJ, Noland CL, et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling. Cell Rep. 2020;31:107809.
   PubMedGoogle Scholar
• Genentech. Therapeutic compounds and methods of use. WO2021097110; 2021
   Google Scholar
• Genentech. Heterocyclic compounds as inhibitors of TEAD for treating cancer and their preparation. WO2022020716; 2022
   Google Scholar
• Genentech. Therapeutic compounds. WO2021108483; 2021
   Google Scholar
• Genentech. Heterobifunctional molecules as TEAD inhibitors. WO2021178339; 2021
   Google Scholar
• Ikena Oncology. TEAD inhibitors and uses thereof. WO2020243423; 2020
   Google Scholar
• Basilea. 1,2,4-Oxadiazol-5-one derivatives for the treatment of cancer. WO2021018869; 2021
   Google Scholar
• Furet P, Salem B, Mesrouze Y, et al. Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP Omega-Loop sequence. Bioorg Med Chem Lett. 2019;29:2316–2319.
   PubMed Web of Science ®Google Scholar
• Novartis. Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors. WO2021186324; 2021
   Google Scholar
• Sanofi. Preparation of (1H-indol-5-yl)acrylamide derivatives as inhibitors of TEAD proteins and the hippo YAP/TAZ signaling cascade for the treatment of cancer. WO2021204823; 2021
   Google Scholar
• Sanofi. Preparation and anticancer activity of acrylamide-substituted indanes. WO2022023460; 2022
   Google Scholar
• Merck. Tricyclic heterocycles useful as TEAD binders and their preparation. WO2021224291; 2021
   Google Scholar
• Merck. Preparation of tricyclic heterocycles for treating or preventing conditions affected by inhibiting YAP-TEAD and/or TAZ-TEAD interaction. WO2022018072; 2022
   Google Scholar
• Pobbati AV, Mejuch T, and Chakraborty S, et al. Identification of quinolinols as activators of TEAD-dependent transcription. ACS Chem Biol. 2019;14:2909–2921.
   PubMedGoogle Scholar
• Adihou H, Gopalakrishnan R, Förster T, et al. A protein tertiary structure mimetic modulator of the hippo signalling pathway. Nat Commun. 2020;11:5425.
   PubMedGoogle Scholar
• Sturbaut M, Bailly F, Coevoet M, et al. Discovery of a cryptic site at the interface 2 of TEAD – Toward new anti-cancer compounds. Eur J Med Chem. 2021;226:113835.
   PubMedGoogle Scholar
• Pobbati AV, Han X, and Hung AW, et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure. 2015;23:2076–2086.
   PubMed Web of Science ®Google Scholar
• Kaneda A, Seike T, Danjo T, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res. 2020;10:4399–4415.
   PubMedGoogle Scholar
• Karatas H, Akbarzadeh M, Adihou H, et al. Discovery of covalent inhibitors targeting the transcriptional enhanced associate domain central pocket. J Med Chem. 2020;63:11972–11989.
   PubMedGoogle Scholar
• Lu W, Wang J, Li Y, et al. Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors. Eur J Med Chem. 2019;184:111767.
   PubMed Web of Science ®Google Scholar
• Landin Malt A, Cagliero J, Legent K, et al. Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of livin. PLoS One. 2012;7:e45498.
   PubMedGoogle Scholar
• Knight JF, Shepherd CJ, Rizzo S, et al. TEAD1 and C-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008;99:1849–1858.
   PubMed Web of Science ®Google Scholar
• Joo JS, Cho SY, Rou WS, et al. TEAD2 as a novel prognostic factor for hepatocellular carcinoma. Oncol Rep. 2020;43:1785–1796.
   PubMed Web of Science ®Google Scholar
• Diepenbruck M, Waldmeier L, Ivanek R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, Zyxin expression and epithelial-mesenchymal transition. J Cell Sci. 2014;127:1523–1536.
   PubMedGoogle Scholar
• Drexler R, Fahy R, Küchler M, et al. Association of subcellular localization of TEAD transcription factors with outcome and progression in pancreatic ductal adenocarcinoma. Pancreatology. 2021;21:170–179.
   PubMed Web of Science ®Google Scholar
• Lee H, Hwang SJ, Kim HR, et al. Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta. 2016;1859:599–611.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang G, Yang Y, et al. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2016;35:2789–2800.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Wang Z, Li LH, et al. Vestigial like family member 3 is a novel prognostic biomarker for gastric cancer. World J Clin Cases. 2019;7:1954–1963.
   PubMedGoogle Scholar
• Qi Y, Yu J, Han W, et al. Splicing Isoform of TEAD4 attenuates the hippo-YAP signalling to inhibit tumour proliferation. Nat Commun. 2016;7(ncomms11840).
   Google Scholar
• Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17:2054–2060.
   PubMed Web of Science ®Google Scholar
• Dong J, Feldmann G, Huanget J, et al. Elucidation of a universal size- control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133.
   PubMed Web of Science ®Google Scholar
• Pearson JD, Huang K, and Pacal M, et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. 2021;39:1115–1134.
   PubMed Web of Science ®Google Scholar
• Pearson JD. Bremner R simplifying cancer: binary pan-cancer superclasses stratified by opposite YAP/TEAD effects. Mol Cell Oncol. 2021;8:1981111.
   PubMedGoogle Scholar
• Ma S, Tang T, Probst G, et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022;13:1061.
   PubMedGoogle Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589.
   PubMed Web of Science ®Google Scholar
• Liberelle M, Toulotte F, and Renault N, et al. Toward the design of selective ligands of TEADs C-terminal domain. J Med Chem. 2022;65:5926–5940.
   PubMedGoogle Scholar
• Li J, Tiwari M, Xu X, et al. TEAD1 and TEAD3 play redundant roles in the regulation of human epidermal proliferation. J Invest Dermatol. 2020;140:2081–4.e4.
   PubMedGoogle Scholar
• Zhang J, Liu P, Tao J, et al. TEA domain transcription factor 4 is the major mediator of yes-associated protein oncogenic activity in mouse and human hepatoblastoma. Am J Pathol. 2019;189:1077–1090.
   PubMed Web of Science ®Google Scholar
• Corvaisier M, Bauzone M, Corfiotti F, et al. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: implication in chemoresistance and cancer relapse. Oncotarget. 2016;7:56700–56712.
   Google Scholar
• Zhao Y, Khanal P, Savage P, et al. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a hippo-independent pathway. Cancer Res. 2014;74:4493–4503.
   PubMed Web of Science ®Google Scholar
• Gujral T, and Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci USA. 2017;114:E3729–E3738.
   PubMedGoogle Scholar